Home Search SiteMap Contact Us Forum Videos Store Physician Board
Advertisement

Leukemia Leukemia Treatment

Cutting Edge Cancer Treatment: An Interview with a Doctor on the Front Lines


Author:

Charles Schiffer, MD

Karmanos Cancer Institute , Detroit, Michigan

Medically Reviewed On: January 08, 2002

by Erica Heilman

Cancer has a new and formidable opponent. It's called molecular biology.

Researchers are currently designing smart new drugs that identify and attack cancer cells on the molecular level, resulting in fewer toxic side effects, and prolonged life.

Dr. Charles Schiffer has followed the development of these drugs from their origins in research, and is now using them to treat patients. A professor of Medicine and Oncology at the Karmanos Cancer Institute at Wayne State University in Detroit, Dr. Schiffer describes how cancer works, how these new drugs work, and how they stand to change the face of cancer treatment as we have known it.

In order to understand how these cancer drugs work, could you first describe how cancer cells behave in the body?
Normally the growth of cells is a very orderly process. The body tells normal cells when they should proliferate or grow, and when they should mature into cells that can perform the specialized functions of that particular organ. In most organs this is a tightly regulated process where the body knows how to turn cell growth on and off.

In cancer, this tightly regulated process breaks down and cancer cells grow beyond where a normal cell would stop growing. Cancer cells invade nearby tissue or they invade the blood stream and travel to other parts of the body. They don't obey the normal mechanisms that either turn on or turn off cell growth.

Why are cancer cells so resistant?
The following analogy for the blood system helps to answer that question. You have a series of very, very young cells called "stem cells", which are like infants. They mature over a certain period of time and become functional adults - red cells, platelets, white cells. Normally, around half of these stem cells are committed to maturing into the adult cells. The other half remain as infants and either sleep in a resting phase, or divide and create more infant stem cells.

Many cancers seem to start because of mutations that occur in these long-lived stem cells. Nature has already perfected the means of keeping these particular cells alive for decades. Thus, it's tough to cure most cancers because they tend to develop in this subpopulation of very resistant cells.

How do these new, targeted drugs work to fight cancer?
The mutations that produce either abnormal enzymes or cell receptors that drive cancer cells are different in different types of cancer, and some mutations are very unique. The targeted drugs are designed to identify the particular mutation and its product, and inhibit those cells that contain the mutation.

By "inhibiting", do you mean that the drug kills the cancer cells?
Some of these targeted drugs kill the cells. Some just inhibit cell growth or spread. They decrease the size of a tumor without necessarily eliminating it.

Page 1 of 2 Next Page >>

RELATED PROGRAMS
Video - Leukemia Explained Transcript
Advertisement